Incorporating biomarkers like soluble P- and E-selectin or NET-derived components into clinical risk scores could enable tailored anticoagulation strategies, especially in complex scenarios such as cancer-associated thrombosis, autoimmune disorders, and post-surgical care. Here, SELE is linked to deep vein thrombosis.